An alternative catalytic cycle for selective methane oxidation to methanol with Cu clusters in zeolites.

The partial oxidation of methane to methanol catalyzed by Cu-exchanged zeolites involves at present a three-step procedure that requires changing reaction conditions along the catalytic cycle. In this work we present an alternative catalytic cycle for selective methane conversion to methanol using as active species small Cu clusters supported on CHA zeolite. Periodic DFT calculations show that molecular O is easily activated on Cu clusters producing bi-coordinated O atoms able to dissociate homolytically a CH bond from CH and to react with the radical-like non-adsorbed methyl intermediate formed producing methanol, while competitive overoxidation to CO is energetically disfavored.

Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetes.

Background: The diabetogenic effect of statins has been well established by clinical trials, Mendelian randomisation studies and meta-analyses. According to large clinical trials, PCSK9 inhibitors (PCSK9i) have no deleterious impact on glucose metabolism. However, few real-life studies have yet evaluated the long-term effects of these drugs on glucose homeostasis and their impact on new-onset diabetes (NODM).

Effect of Framework Composition and NH on the Diffusion of Cu in Cu-CHA Catalysts Predicted by Machine-Learning Accelerated Molecular Dynamics.

Cu-exchanged zeolites rely on mobile solvated Cu cations for their catalytic activity, but the role of the framework composition in transport is not fully understood. Ab initio molecular dynamics simulations can provide quantitative atomistic insight but are too computationally expensive to explore large length and time scales or diverse compositions. We report a machine-learning interatomic potential that accurately reproduces ab initio results and effectively generalizes to allow multinanosecond simulations of large supercells and diverse chemical compositions.

Age and Red Blood Cell Parameters Mainly Explain the Differences Between HbA1c and Glycemic Management Indicator Among Patients With Type 1 Diabetes Using Intermittent Continuous Glucose Monitoring.

Background: Glycated hemoglobin (HbA1c) is the gold standard to assess glycemic control in patients with diabetes. Glucose management indicator (GMI), a metric generated by continuous glucose monitoring (CGM), has been proposed as an alternative to HbA1c, but the two values may differ, complicating clinical decision-making. This study aimed to identify the factors that may explain the discrepancy between them.